Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the emotional and psychological impact of severe alopecia areata on patients, emphasizing feelings of loss, vulnerability, and self-identity changes, and reports no new results.

This review examines various immunomodulatory therapies for cutaneous lymphoma and notes that they are most effective in the disease's early stages.

This review summarizes therapeutic advances reported in English-language literature from December 1987 to December 1988 and states no new clinical results.

This study found that applying topical thymidine dinucleotide (pTT) to newborn mice before UV exposure delayed and reduced melanoma development compared to untreated controls.

This review of interventions for alopecia areata found no significant treatment benefits for hair growth compared to placebo, indicating a need for larger, well-conducted studies.

This review noted that alopecia areata is an autoimmune disease impacting hair follicles and offered insights into its complex pathogenesis involving immune responses, while highlighting ongoing research into new treatments such as Janus kinase inhibitors and other immunomodulatory drugs.

This review outlines the development, applications, and challenges of microneedle-based drug delivery from 2000-2019, particularly highlighting fabrication techniques, but reports no new clinical results.

This study found that intralesional triamcinolone acetonide was most effective for hair regrowth in localized alopecia areata, with betamethasone valerate foam also being beneficial, while tacrolimus ointment showed no significant effect.

This review discusses the variability and limitations of treatments for severe alopecia areata, noting some patients may achieve cosmetic hair regrowth with treatment, while others experience persistent hair loss or relapse.

The researchers reported that carnosic acid and carnosol, extracts from rosemary leaves, specifically inhibit S. aureus virulence expression, suggesting potential topical treatments for atopic dermatitis flares.

This review suggests that oral prednisolone pulse therapy and oral inosiplex may be effective for alopecia areata, but robust evidence from randomized controlled trials is lacking, highlighting the need for better-designed future studies.

This review focuses on the medical treatment of common nonscarring alopecias, including androgenetic alopecia, alopecia areata, and telogen effluvium, and reports no new clinical results.

This study reports that combination therapy with oral steroids, anthralin, and minoxidil yielded effective cosmetic responses in 80% of patients with treatment-resistant extensive alopecia areata.

This chapter reviews treatments for alopecia areata and androgenetic alopecia but presents no new clinical findings, emphasizing the need for more effective and safe hair growth promoters.

In this prospective clinical trial, azathioprine with steroid minipulse therapy and methotrexate with steroid minipulse therapy both improved hair regrowth in alopecia areata patients, but methotrexate showed slightly higher efficacy.

This review examines current treatment options for alopecia areata and highlights the challenges due to limited evidence-based data and unpredictability in disease progression.

The document concludes that different types of hair loss have specific treatments, and early diagnosis is crucial for preventing permanent hair loss.

This study reported that a modified version of Thymosin beta 4, called PEG-rTβ4, demonstrated potential as a treatment for acute myocardial infarction by improving cardiac function and reducing cell death via specific biochemical pathways, suggesting its promise in drug development efforts.

In a mouse model of peripheral vascular disease, this study found that recombinant thymosin β4 treatment increased expression levels of certain proteins, promoting angiogenesis.

This review explores the mechanisms and clinical applications of thymosin β4, highlighting its potential in various medical fields, but it presents no new research findings.

This article reviews alopecia areata as a chronic autoimmune disease affecting hair follicles and discusses its association with other autoimmune conditions, but provides no new clinical findings.

This study found that ethanol extract of Thevetia peruviana bark demonstrated significant antinociceptive activity in mice, suggesting potential for developing new analgesic drugs.

This source reports that thymosin beta 4 accelerated dermal wound repair in phase 2 clinical trials for pressure ulcers, stasis ulcers, and epidermolysis bullosa wounds and was well tolerated.

This study presents evidence that specific thymus-derived peptides affect human hair follicle growth, identifying thymulin as a potential hair growth stimulator despite interindividual response variations.

This study found that Dex-loaded hyaluronic acid hydrogel microneedles significantly reduced pain in an acute inflammatory visceral pain model without sedation, suggesting a promising and patient-friendly alternative to intravenous delivery.

This study observed that thymol from Origanum marjoram essential oil significantly promoted hair regrowth and reduced inflammation in cyclophosphamide-induced alopecia in rabbits, with effects that were comparable to or exceeded those of betamethasone, highlighting its potential as a safer treatment alternative.

This review discusses the molecular mechanisms and clinical applications of thymosin β4, highlighting its potential benefits for inflammation, wound healing, tumor metastasis, and other medical conditions but reports no new experimental results.

Thymosin β4 helps heal wounds, grow hair, and improve blood vessel formation.

Thymic peptides can either promote or inhibit human hair growth.

This study found that several small molecule peptides based on thymosin β4 significantly promoted cell proliferation related to wound healing, angiogenesis, and hair growth more effectively than established positive controls.